Enliven Therapeutics, Inc. (NASDAQ:ELVN – Get Free Report) CFO Benjamin Hohl sold 14,000 shares of Enliven Therapeutics stock in a transaction that occurred on Thursday, April 11th. The stock was sold at an average price of $24.72, for a total transaction of $346,080.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.
Benjamin Hohl also recently made the following trade(s):
- On Wednesday, March 27th, Benjamin Hohl sold 3,250 shares of Enliven Therapeutics stock. The shares were sold at an average price of $18.25, for a total transaction of $59,312.50.
- On Tuesday, February 27th, Benjamin Hohl sold 3,250 shares of Enliven Therapeutics stock. The shares were sold at an average price of $16.97, for a total transaction of $55,152.50.
- On Monday, January 29th, Benjamin Hohl sold 3,250 shares of Enliven Therapeutics stock. The shares were sold at an average price of $15.81, for a total transaction of $51,382.50.
Enliven Therapeutics Stock Performance
Shares of Enliven Therapeutics stock opened at $17.30 on Thursday. The company has a market capitalization of $712.76 million, a P/E ratio of -7.90 and a beta of 1.06. The company has a fifty day moving average of $16.98 and a 200 day moving average of $14.31. Enliven Therapeutics, Inc. has a fifty-two week low of $9.80 and a fifty-two week high of $26.00.
Wall Street Analysts Forecast Growth
Separately, Mizuho started coverage on shares of Enliven Therapeutics in a research report on Tuesday, April 9th. They set a “buy” rating and a $34.00 price objective for the company.
Get Our Latest Stock Analysis on Enliven Therapeutics
Institutional Trading of Enliven Therapeutics
Several hedge funds have recently bought and sold shares of ELVN. Barclays PLC purchased a new stake in shares of Enliven Therapeutics during the 1st quarter valued at about $158,000. Bank of New York Mellon Corp purchased a new stake in shares of Enliven Therapeutics during the 1st quarter valued at about $335,000. Tower Research Capital LLC TRC purchased a new stake in shares of Enliven Therapeutics during the 1st quarter valued at about $36,000. Citigroup Inc. purchased a new stake in shares of Enliven Therapeutics during the 1st quarter valued at about $247,000. Finally, Dimensional Fund Advisors LP purchased a new stake in shares of Enliven Therapeutics during the 1st quarter valued at about $217,000. Hedge funds and other institutional investors own 95.08% of the company’s stock.
Enliven Therapeutics Company Profile
Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.
Featured Articles
- Five stocks we like better than Enliven Therapeutics
- 5 Top Rated Dividend Stocks to Consider
- United Airlines Soars on Earnings Beat
- What Are the FAANG Stocks and Are They Good Investments?
- J.B. Hunt Hits the Skids: Lower Prices to Come
- 3 Warren Buffett Stocks to Buy Now
- Predicting a Bear Market: 7 Signs and Why it’s Tough to Do
Receive News & Ratings for Enliven Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enliven Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.